How cost-effective is donanemab as an Alzheimer’s treatment, and why did NICE reject its routine use on the NHS?
In June 2025, NICE concluded that the donanemab Alzheimer’s treatment cost-effectiveness does not justify routine ...
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.